Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Francisco Javier Ampudia Blasco"'
Autor:
Alba Galdón Sanz-Pastor, Alicia Justel Enríquez, Ana Sánchez Bao, Francisco Javier Ampudia-Blasco
Publikováno v:
Frontiers in Endocrinology, Vol 15 (2024)
Insulin is an essential drug in the treatment of diabetes, often necessary for managing hyperglycemia in type 2 diabetes mellitus (T2DM). It should be considered in cases of severe hyperglycemia requiring hospitalization, after the failure of other t
Externí odkaz:
https://doaj.org/article/346f9148669d46d8af65175f69463427
Autor:
Juan P. Frias, Thomas Danne, Steven V. Edelman, Sangeeta Sawhney, Michael J Davies, Philip Banks, Francisco Javier Ampudia-Blasco, Wenjun Jiang
Publikováno v:
Diabetes, Obesity and Metabolism. 23:854-860
Sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1/SGLT2 inhibitor, is currently approved in Europe as an adjunct to optimal insulin therapy in adults with type 1 diabetes (T1D) and a body mass index (BMI) ≥ 27 kg/m2 . In this post hoc ana
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::45bccecc7035269f5052e47e5836a197
https://doi.org/10.1111/dom.14271
https://doi.org/10.1111/dom.14271
Autor:
Virginia Bellido, Eva Aguilera, Roque Cardona-Hernandez, Gonzalo Diaz-Soto, Noemi González Pérez de Villar, María J. Picón-César, Francisco Javier Ampudia-Blasco
Publikováno v:
Journal of diabetes science and technology.
New metrics for assessing glycemic control beyond HbA1c have recently emerged due to the increasing use of continuous glucose monitoring (CGM) in diabetes clinical practice. Among them, time in range (TIR) has appeared as a simple and intuitive metri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e75ed3d7e2ff23583d74b68ba96b206
https://pubmed.ncbi.nlm.nih.gov/35470692
https://pubmed.ncbi.nlm.nih.gov/35470692
Autor:
Anders Hasager Boss, Julio Rosenstock, Lizheng Shi, Robert Lubwama, Xuejun Victor Peng, Francisco Javier Ampudia-Blasco, Vivian Fonseca
Publikováno v:
Diabetes, Obesity & Metabolism
Aim To assess the impact of the timing of initiating both basal insulin and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) on reaching glycaemic control targets over 6 and 12 months in people with type 2 diabetes (T2D) uncontrolled on or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f65328f653c1e5d0eb1addcdd5291830
https://doi.org/10.1111/dom.14154
https://doi.org/10.1111/dom.14154
Autor:
Wan Chen Gu Hong, Jordi Ferri, Francisco Javier Ampudia-Blasco, Ramón Martín-Brufau, Marta Peiró, Esther Benito, Sergio Martinez-Hervas, María Jesús Sanz, José Tomás Real
Publikováno v:
Endocrinologia, diabetes y nutricion. 69(9)
The diagnosis of type 1 diabetes mellitus (DM1) has a major impact on young people and their families. Psychosocial factors, patient motivation, participation and acceptance of the disease are essential to achieve good blood glucose control. Our aims
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cf95602c1860129aab6c422a9f877ea
https://pubmed.ncbi.nlm.nih.gov/36470643
https://pubmed.ncbi.nlm.nih.gov/36470643
Publikováno v:
The Lancet Diabetes & Endocrinology. 10:18-19
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::27bdeb30f909dc29c41a39830b76637f
https://doi.org/10.1016/s2213-8587(21)00322-3
https://doi.org/10.1016/s2213-8587(21)00322-3
Autor:
Virgina Bellido, Eva Aguilera, Diego Fernández, Rafael Palomares, Cristobal Morales, Juan Parra, María Teresa Rivero, Pedro Mezquita-Raya, Fernando Gomez-Peralta, Juan José Gorgojo, Francisco Javier Escalada, Ana Chico, Cintia González-Blanco, Roque Cardona-Hernandez, Pedro de Pablos Velasco, Noemí González Pérez de Villar, Francisco Javier Ampudia-Blasco
Publikováno v:
J Diabetes Sci Technol
The flash glucose monitoring (FGM) system FreeStyle Libre® is a device that measures interstitial glucose in a very simple way and indicates direction and speed of glucose change. This allows persons with diabetes to prevent hypoglycemic and hypergl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed13b17c8c2d157e216cf872fc1f9dda
https://doi.org/10.1177/1932296819841911
https://doi.org/10.1177/1932296819841911
Autor:
Brian Larsen Thorsted, Virginia Martín, Pedro Mezquita Raya, Hermione Price, Francisco Javier Ampudia Blasco, Barnaby Hunt, A Basse
Publikováno v:
Diabetes, Obesity & Metabolism
Aim To evaluate the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus comparator regimens for type 2 diabetes in Spain, based on real-world evidence. Materials and methods Clinical data were taken
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3736a64e333898ca1cbcac47f1ff3097
http://europepmc.org/articles/PMC6594226
http://europepmc.org/articles/PMC6594226
Publikováno v:
Nutrients. 14:2593
Thyroid cancer is the most common endocrine malignancy and exhibits rising incidence. Annual incidence varies by sex, age, and geographical location. It has been reported that impairment of vitamin D signalling promotes thyroid cancer progression. Re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ee0f17b0ba4103b1cff83d20ad906ee
https://doi.org/10.3390/nu14132593
https://doi.org/10.3390/nu14132593
Autor:
Pedro José Pinés-Corrales, Francisco Javier Ampudia-Blasco, Rocío Villar-Taibo, Virginia Bellido
Publikováno v:
Diabetes research and clinical practice. 177
The HbA1c value has been the gold standard for evaluating glucose control for decades. However, it has limitations such as the lack of information on glycemic variability or the risk of hypoglycemia. The increasing use of continuous glucose monitorin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d2c92eeded4784517520f064627776c
https://pubmed.ncbi.nlm.nih.gov/34126129
https://pubmed.ncbi.nlm.nih.gov/34126129